Mark M. Smits

5.1k total citations · 5 hit papers
68 papers, 3.8k citations indexed

About

Mark M. Smits is a scholar working on Endocrinology, Diabetes and Metabolism, Surgery and Molecular Biology. According to data from OpenAlex, Mark M. Smits has authored 68 papers receiving a total of 3.8k indexed citations (citations by other indexed papers that have themselves been cited), including 50 papers in Endocrinology, Diabetes and Metabolism, 25 papers in Surgery and 11 papers in Molecular Biology. Recurrent topics in Mark M. Smits's work include Diabetes Treatment and Management (42 papers), Diabetes Management and Research (18 papers) and Pancreatic function and diabetes (17 papers). Mark M. Smits is often cited by papers focused on Diabetes Treatment and Management (42 papers), Diabetes Management and Research (18 papers) and Pancreatic function and diabetes (17 papers). Mark M. Smits collaborates with scholars based in Netherlands, United States and Denmark. Mark M. Smits's co-authors include Daniël H. van Raalte, Marcel H.A. Muskiet, Lennart Tonneijck, Mark H.H. Kramer, Jaap A. Joles, Michaëla Diamant, Erwin J. M. van Geenen, Erik J.M. van Bommel, Hiddo J.L. Heerspink and Trynke Hoekstra and has published in prestigious journals such as Diabetes Care, Diabetes and Gut.

In The Last Decade

Mark M. Smits

66 papers receiving 3.7k citations

Hit Papers

5 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Glomerular Hyperfiltration in Diabetes: Mechanisms, Clinical Significance, and Treatment

2017 595 citations Lennart Tonneijck, Marcel H.A. Muskiet et al. profile →
GLP-1 and the kidney: from physiology to pharmacology and outcomes in diabetes

2017 294 citations Marcel H.A. Muskiet, Lennart Tonneijck et al. Nature Reviews Nephrology profile →
Continuous glucose monitoring for patients with type 1 diabetes and impaired awareness of hypoglycaemia (IN CONTROL): a randomised, open-label, crossover trial

2016 289 citations Mark M. Smits, Mark H.H. Kramer et al. The Lancet Diabetes & Endocrinology profile →
The renal hemodynamic effects of the SGLT2 inhibitor dapagliflozin are caused by post-glomerular vasodilatation rather than pre-glomerular vasoconstriction in metformin-treated patients with type 2 diabetes in the randomized, double-blind RED trial

2019 253 citations Erik J.M. van Bommel, Marcel H.A. Muskiet et al. Kidney International profile →
Safety of Semaglutide

2021 174 citations Mark M. Smits, Daniël H. van Raalte profile →

Peers

Countries citing papers authored by Mark M. Smits

Since Specialization

Citations

This map shows the geographic impact of Mark M. Smits's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mark M. Smits with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mark M. Smits more than expected).

Fields of papers citing papers by Mark M. Smits

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mark M. Smits. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mark M. Smits. The network helps show where Mark M. Smits may publish in the future.

Co-authorship network of co-authors of Mark M. Smits

This figure shows the co-authorship network connecting the top 25 collaborators of Mark M. Smits. A scholar is included among the top collaborators of Mark M. Smits based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mark M. Smits. Mark M. Smits is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Female glucagon receptor knockout mice are prone to steatosis but resistant to weight gain when fed a MASH‐promoting GAN diet and a high‐fat diet 2025 ·Physiological Reports ·Katrine D. Galsgaard, (unknown), Jenna Elizabeth Hunt, Mark M. Smits, Trisha J. Grevengoed, Christina Christoffersen, Nils J. Færgeman, Jesper F. Havelund, Nicolai J. Wewer Albrechtsen, Jens J. Holst	1
2	l-valine is a powerful stimulator of GLP-1 secretion in rodents and stimulates secretion through ATP-sensitive potassium channels and voltage-gated calcium channels 2024 ·Nutrition and Diabetes ·(unknown), Mark M. Smits, Katrine D. Galsgaard, (unknown), (unknown), Mette M. Rosenkilde, Jens J. Holst	1
3	Endogenous glucagon‐like peptide (GLP)‐1 as alternative for GLP‐1 receptor agonists: Could this work and how? 2023 ·Diabetes/Metabolism Research and Reviews ·Mark M. Smits, Jens J. Holst	11
4	SAT037 Glucagon-like Peptide-1 Receptor Knockout Mice Do Not Compensate For The Lack Of Incretin Action By Increasing Glucose-dependent Insulinotropic Polypeptide Secretion 2023 ·Journal of the Endocrine Society ·Katrine D. Galsgaard, Hannelouise Kissow, Mark M. Smits, (unknown)	0
5	Kidney hemodynamic function in men and postmenopausal women with type 2 diabetes and preserved kidney function 2021 ·American Journal of Physiology-Renal Physiology ·Daan van Velzen, Mark M. Smits, Erik J.M. van Bommel, Marcel H.A. Muskiet, Lennart Tonneijck, Mark H.H. Kramer, Jaap A. Joles, Martin den Heijer, Natalie Nokoff, Petter Bjornstad, Daniël H. van Raalte	2
6	Postprandial renal haemodynamic effects of the dipeptidyl peptidase‐4 inhibitor linagliptin versus the sulphonylurea glimepiride in adults with type 2 diabetes ( RENALIS ): A predefined substudy of a randomized, double‐blind trial 2021 ·Diabetes Obesity and Metabolism ·Marcel H.A. Muskiet, Lennart Tonneijck, Mark M. Smits, Mark H.H. Kramer, D. Margriet Ouwens, Bolette Hartmann, Jens J. Holst, A.H. Jan Danser, Jaap A. Joles, Daniël H. van Raalte	6
7	Liraglutide and sitagliptin have no effect on intestinal microbiota composition: A 12-week randomized placebo-controlled trial in adults with type 2 diabetes 2021 ·Diabetes & Metabolism ·Mark M. Smits, (unknown), Hilde Herrema, Mark Davids, Mark H.H. Kramer, Albert K. Groen, Clara Belzer, Willem M. de Vos, Djuna L. Cahen, Max Nieuwdorp, Daniël H. van Raalte	48
8	The effect of liraglutide and sitagliptin on oxidative stress in persons with type 2 diabetes 2021 ·Scientific Reports ·(unknown), Emil List Larsen, Daniël H. van Raalte, Marcel H.A. Muskiet, Mark M. Smits, Lennart Tonneijck, Jaap A. Joles, Bernt Johan von Scholten, Emilie H. Zobel, Frederik Persson, Trine Henriksen, Lars Jorge Díaz, Tine W. Hansen, Henrik E. Poulsen, Peter Rossing	13
9	Effects of dipeptidyl peptidase‐4 inhibitor linagliptin versus sulphonylurea glimepiride on systemic haemodynamics in overweight patients with type 2 diabetes: A secondary analysis of an 8‐week, randomized, controlled, double‐blind trial 2020 ·Diabetes Obesity and Metabolism ·Jordan M Kraaijenhof, Marcel H.A. Muskiet, Lennart Tonneijck, D. Margriet Ouwens, Mark H.H. Kramer, Daniël H. van Raalte, Mark M. Smits	7
10	Effects of DPP-4 Inhibitor Linagliptin Versus Sulfonylurea Glimepiride as Add-on to Metformin on Renal Physiology in Overweight Patients With Type 2 Diabetes (RENALIS): A Randomized, Double-Blind Trial 2020 ·Diabetes Care ·Marcel H.A. Muskiet, Lennart Tonneijck, Mark M. Smits, (unknown), D. Margriet Ouwens, Bolette Hartmann, Jens J. Holst, Daan J. Touw, A.H. Jan Danser, Jaap A. Joles, Daniël H. van Raalte	11
11	Assessment of real‐time and quantitative changes in renal hemodynamics in healthy overweight males: Contrast‐enhanced ultrasonography vs para‐aminohippuric acid clearance 2019 ·Microcirculation ·Marcel H.A. Muskiet, Anna L. Emanuel, Mark M. Smits, Lennart Tonneijck, Rick I. Meijer, Jaap A. Joles, Erik H. Serné, Daniël H. van Raalte	6
12	The renal hemodynamic effects of the SGLT2 inhibitor dapagliflozin are caused by post-glomerular vasodilatation rather than pre-glomerular vasoconstriction in metformin-treated patients with type 2 diabetes in the randomized, double-blind RED trial breakdown → 2019 ·Kidney International ·Erik J.M. van Bommel, Marcel H.A. Muskiet, Michaël J.B. van Baar, Lennart Tonneijck, Mark M. Smits, Anna L. Emanuel, Andrea Božović, A.H. Jan Danser, Frank Geurts, Ewout J. Hoorn, Daan J. Touw, Emil List Larsen, Henrik E. Poulsen, Mark H.H. Kramer, Max Nieuwdorp, Jaap A. Joles, Daniël H. van Raalte	253
13	GLP-1 receptor agonists do not affect sodium intake: Exploratory analyses from two randomized clinical trials 2019 ·Nutrition ·Mark M. Smits, Jennifer S. ten Kulve, Liselotte van Bloemendaal, Lennart Tonneijck, Marcel H.A. Muskiet, Mark H.H. Kramer, Richard G. IJzerman, Daniël H. van Raalte	2
14	Effect of immediate and prolonged GLP‐1 receptor agonist administration on uric acid and kidney clearance: Post‐hoc analyses of four clinical trials 2018 ·Diabetes Obesity and Metabolism ·Lennart Tonneijck, Marcel H.A. Muskiet, Mark M. Smits, Petter Bjornstad, Mark H.H. Kramer, Michaëla Diamant, Ewout J. Hoorn, Jaap A. Joles, Daniël H. van Raalte	30
15	Postprandial renal haemodynamic effect of lixisenatide vs once‐daily insulin‐glulisine in patients with type 2 diabetes on insulin‐glargine: An 8‐week, randomised, open‐label trial 2017 ·Diabetes Obesity and Metabolism ·Lennart Tonneijck, Marcel H.A. Muskiet, Mark M. Smits, Trynke Hoekstra, Mark H.H. Kramer, A.H. Jan Danser, Michaëla Diamant, Jaap A. Joles, Daniël H. van Raalte	55
16	GLP-1 and the kidney: from physiology to pharmacology and outcomes in diabetes breakdown → 2017 ·Nature Reviews Nephrology ·Marcel H.A. Muskiet, Lennart Tonneijck, Mark M. Smits, Michaël J.B. van Baar, Mark H.H. Kramer, Ewout J. Hoorn, Jaap A. Joles, Daniël H. van Raalte	294
17	The effects of GLP-1 based therapies on postprandial haemodynamics: Two randomised, placebo-controlled trials in overweight type 2 diabetes patients 2016 ·Diabetes Research and Clinical Practice ·Mark M. Smits, Lennart Tonneijck, Marcel H.A. Muskiet, Trynke Hoekstra, Mark H.H. Kramer, Michaëla Diamant, Daniël H. van Raalte	14
18	Cardiovascular, renal and gastrointestinal effects of incretin-based therapies: an acute and 12-week randomised, double-blind, placebo-controlled, mechanistic intervention trial in type 2 diabetes 2015 ·BMJ Open ·Mark M. Smits, Lennart Tonneijck, Marcel H.A. Muskiet, Trynke Hoekstra, Mark H.H. Kramer, (unknown), Djuna L. Cahen, Michaëla Diamant, Daniël H. van Raalte	23
19	Pleiotropic effects of type 2 diabetes management strategies on renal risk factors 2015 ·The Lancet Diabetes & Endocrinology ·Marcel H.A. Muskiet, Lennart Tonneijck, Mark M. Smits, Mark H.H. Kramer, Hiddo J.L. Heerspink, Daniël H. van Raalte	63
20	The gut–renal axis: do incretin-based agents confer renoprotection in diabetes? 2013 ·Nature Reviews Nephrology ·Marcel H.A. Muskiet, Mark M. Smits, Linde M. Morsink, Michaëla Diamant	157

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact